|
|
|
IMF PATIENT PUBLICATIONS:
|
|
| |
IMF publications are a valuable resource for patients, family members and medical professionals.
|
|
|
| |
IMF Multiple Myeloma Patient Handbook 2008/2009
|
|
|
Basic information for myeloma patients and caregivers. A good starting point in your search for information.
|
|
|
|
 |
|
|
| |
New! Updated Concise Review 2008/2009
|
|
|
Overview of the history of myeloma, pathophysiology, clinical features, and tx options. The focus is practical, founded upon the most recent research developments in the field.
|
|
|
|
|
|
|
| |
International Staging System (ISS)
|
|
|
The International Myeloma Foundation is proud to sponsor the International Staging System (ISS). The ISS is a collaborative research initiative with twenty myeloma institutions from around the world.
|
|
|
|
|
|
|
| |
The Myeloma Matrix
|
|
|
The Myeloma Matrix provides updated information about drugs beginning with pre-clinical developments and tracks drugs as they proceed through Phases I – III of clinical trials, to FDA approval.
|
|
|
|
|
|
|
|
|
|
IMF PUBLICATIONS - THE UNDERSTANDING SERIES:
|
|
| |
The IMF is committed to making information on myeloma treatments available in a format that is easy to read and understand.
|
|
|
| |
New! Understanding Doxil® in Myeloma
|
|
|
Doxil® is a form of the chemotherapy agent doxorubicin. The FDA has recently approved Doxil® in combination with VELCADE® to treat patients with myeloma who have not previously received VELCADE® and have received at least one prior therapy.
|
|
|
|
|
|
|
| |
Understanding Stem Cell Transplant
|
|
|
What are the benefits and risks of high-dose chemotherapy with blood stem cell rescue as part of the treatment for myeloma?
|
|
|
|
|
|
|
| |
Understanding VELCADE® (bortezomib) for Injection Therapy
|
|
|
Part of the IMF's Understanding series, this booklet covers the basics, including: What is VELCADE®? How does it work? What are the side effects?
|
|
|
|
|
|
|
| |
Understanding Revlimid®
|
|
|
Learn more about Revlimid® (lenalidomide), recently approved by the FDA for use in myeloma.
|
|
|
|
|
|
|
| |
Understanding Thalidomide Therapy
|
|
|
Using thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades. Much has been learned about how thalidomide works in the treatment of different diseases, and how its side effects can be treated.
|
|
|
|
|
|
|
| |
Understanding Dexamethasone and Other Steroids
|
|
|
After reading this booklet, you should know what dexamethasone is, how it works, possible side effects, and more.
|
|
|
|
|
|
|
| |
Understanding Quadramet®
|
|
|
Quadramet® belongs to a class of drugs called radiopharmaceuticals and is used to treat bone pain that often results when cancer has spread to the bone.
|
|
|
|
|
|
|
| |
Understanding Serum Free Light Chain Assays
|
|
|
Learn more about a new type of laboratory test called the serum Free Light Chain assay. This test is also known as the Freelite™ test.
|
|
|
|
|
|
|
| |
Understanding Bisphosphonate Therapy
|
|
|
What you need to know about bone disease and bisphosphonate therapy. What are bisphosphonates? How do they work? Who should take them and who shouldn't? Side effects.
|
|
|
|
|
|
|
| |
Understanding Trisenox® (arsenic trioxide) injection
|
|
|
Trisenox (arsenic trioxide) injection is a type of anticancer agent that is derived from arsenic, a naturally occurring compound that has been used for over two thousand years in Chinese and western medicine to treat a wide range of disorders.
|
|
|
|
|
|
|
| |
Understanding Anemia and Fatigue
|
|
|
Learn about what you can do and which medications are available to helpyou better manage your fatigue and anemia and enable you to feel better and participate in more activities.
|
|
|
|
|
|
|
| |
Understanding Balloon Kyphoplasty
and Myeloma-Induced Vertebral Compression Fractures
|
|
|
This booklet covers everything you need to know about vertebral compression fractures and kyphoplasty. In PDF form for viewing and downloading.
|
|
|
|
|
|
|
| |
Understanding ZIO-101
(Darinaparsin)
|
|
|
Darinaparsin is a novel, organic arsenic that kills human myeloma cell lines grown in the laboratory. It is also active against human myelomas that have been transplanted into mice. As a form of organic arsenic, Darinaparsin represents a new class of small molecule cancer therapy.
|
|
|
|
|
|
|
|
|
|
IMF PROFESSIONAL PUBLICATIONS:
|
|
|
| |
New! Updated Concise Review 2008/2009
|
|
|
|
Overview of the history of myeloma, pathophysiology, clinical features, and tx options. The focus is practical, founded upon the most recent research developments in the field.
|
|
|
|
|
|
|
| |
New! A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop
|
|
|
Summaries from the workshop sessions in Kos, Greece on 5–30 June, 2007
|
|
|
|
|
|
|
| |
ASCO 2007 Highlights for Physicians
|
|
|
New and updated data on the use of novel therapeutics in combination therapy in patients with newly diagnosed or relapsed/refractory multiple myeloma were presented at the 2007 meeting of the American Society of Clinical Oncology (ASCO), June 1 through 5, in Chicago, Illinois.
|
|
|
|
|
|
|
| |
ASH 2006 Multiple Myeloma Highlights for Physicians
|
|
|
Download and read the PDF of our summary of the 48th Annual Meeting of the American Society for Hematology(ASH).
|
|
|
|
|
|
|
| |
CITINGS
|
|
|
The IMF is pleased to bring you CITINGS, a quarterly publication featuring the most up-to-date information on research advances and new therapies for the treatment for multiple myeloma.
|
|
|
|
|
|
|
| |
Myeloma Management Guidelines: A Consensus Report from the Scientific Advisors of the IMF
|
|
These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. This article appeared in The Hematology Journal (2003) 4, 379-398.
|
|
|
|
|
|
|
|
|
|
|
| |
Myeloma Today: The IMF's Quarterly Newsletter
|
|
|
News about the IMF and multiple myeloma, available online as well as by mail.
|
|
|
|
|
|
|
| |
Sign up for the Myeloma Minute
|
|
|
Subscribe to this free e-mail newsletter for up-to-the "minute" information about myeloma.
|
|
|
|
|
|
|
|
|
|
PUBLICATIONS FROM OTHER AGENCIES AND ORGANIZATIONS:
|
|
|
| |
Chemotherapy and You
|
|
|
This booklet from the National Cancer Institute (NCI) is a guide you can refer to throughout your chemotherapy treatment. It includes facts about chemotherapy and its side effects and also highlights ways
you can care for yourself before, during, and after treatment.
|
|
|
|
|
|
|
| |
Eating Hints for Cancer Patients
Before, During & After Treatment
|
|
|
Your diet is an important part of your treatment for cancer. Eating the right kinds of foods before, during, and after
treatment can help you feel better and stay stronger. The National Cancer Institute (NCI) has prepared this booklet to help you learn about your diet needs during treatment and to help you cope with side effects that may affect eating.
|
|
|
|
|
|
|
| |
Multiple Myeloma Patient Handbook (Canada)
|
|
|
Created by Myeloma Canada
|
|
|
|
|
|
|
| |
NCI Cancer Bulletin
|
|
|
Weekly publication provides useful and authoritative news about important NCI programs and initiatives.
|
|
|
|
|
|
|
| |
Radiation Therapy and You
|
|
|
This booklet from the National Cancer Institute (NCI) is a guide that you can refer to throughout radiation therapy. It has facts about radiation therapy andside effects and describes how you can care for yourself during and after treatment.
|
|
|
|
|
|
|
| |
Facing Forward: Life After Cancer Treatment
|
|
|
A publication from the National Cancer Institute
|
|
|
|
|
|
|
| |
Comprehensive Caregiver's Manual
|
|
|
The International Myeloma Foundation is pleased to offer a comprehensive guide for caregivers.
|
|
|
|
|
|
|
|
|
|
MEETING HIGHLIGHTS FOR PATIENTS:
|
|
|
| |
ASCO Highlights for Physicians and Patients
|
|
|
News from the 2008 ASCO Meeting Compiled by Lynne Lederman, PhD
|
|
|
|
|
|
|
| |
ASH 2008 Highlights for Physicians and Patients
|
|
|
|
News from the 2008 Meeting of the American Society of Hematology Compiled by Lynne Lederman, PhD
|
|
|
|
|
|
|
|
